Alkermes PLC ALKS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALKS is a good fit for your portfolio.
News
-
Alkermes to Report First Quarter Financial Results on May 1, 2024
-
Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
-
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
-
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
-
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
-
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
-
Alkermes shares surge after settlement with Teva on alcohol dependence treatment
Trading Information
- Previous Close Price
- $23.76
- Day Range
- $23.48–23.87
- 52-Week Range
- $22.01–33.71
- Bid/Ask
- $23.92 / $23.87
- Market Cap
- $4.04 Bil
- Volume/Avg
- 2.4 Mil / 2.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- 14.14
- Price/Sales
- 2.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,100
- Website
- https://www.alkermes.com
Competitors
Valuation
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Price/Earnings (Normalized) | 14.14 | 13.97 |
Price/Book Value | 3.30 | 5.10 |
Price/Sales | 2.42 | 4.09 |
Price/Cash Flow | 9.21 | 18.40 |
Price/Earnings
ALKS
JNJ
Financial Strength
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Quick Ratio | 2.13 | 0.91 |
Current Ratio | 2.86 | 1.16 |
Interest Coverage | 17.96 | 18.88 |
Quick Ratio
ALKS
JNJ
Profitability
|
Metric
|
ALKS
|
JNJ
|
|---|---|---|
Return on Assets (Normalized) | 18.90% | 13.98% |
Return on Equity (Normalized) | 33.67% | 35.02% |
Return on Invested Capital (Normalized) | 24.95% | 22.24% |
Return on Assets
ALKS
JNJ
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Tmqbrwbnn | Bcrk | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Swngqhsmjr | Qqggr | $67.6 Bil | |
HLN
| Haleon PLC ADR | Ytgbdnkt | Lwmqy | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Twphfjlg | Pyjv | $14.3 Bil | |
VTRS
| Viatris Inc | Mspymjlyt | Zgf | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zvhxlyr | Tvddl | $11.9 Bil | |
CTLT
| Catalent Inc | Trlnzmmp | Pttyqgl | $10.0 Bil | |
PRGO
| Perrigo Co PLC | Blwmmtmx | Xsr | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Gkslpbv | Dhpy | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ptqnhzft | Vjssxbn | $3.4 Bil |